SCHEMBL386324

SCHEMBL386324

Cc1cc(-c2cc(-c3ccccc3Cl)[n+]([O-])cn2)ccc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.53
TLR8 Q9NR97 4/20 0.39
ESR2 Q92731 2/20 0.39
CDC7 O00311 1/20 0.39
CSNK2A2 P19784 1/20 0.39
CLK1 P49759 1/20 0.39
GSK3B P49841 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
CSNK2A3 Q8NEV1 1/20 0.39
TNKS2 Q9H2K2 1/20 0.36
USP7 Q93009 1/20 0.36
ABL1 P00519 2/20 0.35
HSD11B1 P28845 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL385119 0.84 IDO1 (0.41) PIM1TLR8CDC7CSNK2A2CLK1
SCHEMBL385779 0.83 TLR8 (0.45) PIM1TLR8ESR2CDC7CSNK2A2
SCHEMBL385438 0.80 PIM1 (0.41) PIM1ESR2CDC7CSNK2A2CLK1
SCHEMBL385493 0.80 TLR8 (0.43) PIM1TLR8ESR2CDC7CSNK2A2
SCHEMBL383765 0.80 TP53 (0.40) PIM1TLR8ESR2CDC7CSNK2A2
SCHEMBL386149 0.79 PIM1 (0.38) PIM1TLR8ESR2CDC7CSNK2A2
SCHEMBL383607 0.79 PIM1 (0.38) PIM1TLR8ESR2CDC7CSNK2A2
SCHEMBL384944 0.79 TLR8 (0.38) PIM1TLR8ESR2CDC7CSNK2A2
SCHEMBL385491 0.79 TLR8 (0.36) PIM1TLR8ESR2CDC7CSNK2A2
SCHEMBL383422 0.79 PIM1 (0.37) PIM1TLR8ESR2CDC7CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 EP disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed
EP-1948617-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS Exelixis, Inc. (US) 2008-07-30 EP disclosed
WO-2007048065-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators CSNK2A1, CSNK1A1, CSNK2A2 PIM1 429/4885TLR8 3200/4885ESR2 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.